Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Institut de Recherches Internationales Servier (France)
Woman and Man Max 99 years
Institut de Recherches Internationales Servier (France)
Update Il y a 4 ans
Phase I dose-escalation study of S 78454 in patients with solid tumour
Not provided at time of registration and not expected to be available in the future
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Institut de Recherches Internationales Servier (France)
Update Il y a 5 ans
A one-year multicentre, international, randomised, double-blind study with comparison of benfluorex versus an oral anti-diabetic in combination with sulfonylurea administered orally for the treatment of type two diabetes
Not provided at time of registration and not expected to be available in the future
Country
France
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Institut de Recherches Internationales Servier (France)
Update Il y a 4 ans
Efficacy of agomelatine given orally on rest/activity circadian rhythms in outpatients with major depressive disorder: a randomised, double-blind international study with parallel groups versus Selective Serotonin Reuptake Inhibitor (SSRI). Six-week treatment plus optional continuation for 18 weeks
Not provided at time of registration and not expected to be available in the future
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Institut de Recherches Internationales Servier (France)
Update Il y a 4 ans
Efficacy and safety of the S 05985 combination compared with each individual component: randomised, double-blind, placebo-controlled study over eight weeks in hypertensive patients
Not provided at time of registration and not expected to be available in the future
Country
France
,
Hungary
,
Latvia
,
Lithuania
,
Russian Federation
,
Ukraine
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Institut de Recherches Internationales Servier (France)
Update Il y a 4 ans
Efficacy and safety of agomelatine oral administration (25 to 50 mg/day) in elderly patients suffering from major depressive disorder: an 8-week, randomised, double-blind, flexible-dose, parallel groups, placebo-controlled, international, multicentre study followed by an extension double-blind treatment period of 16 weeks
Not provided at time of registration and not expected to be available in the future
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Institut de Recherches Internationales Servier (France)
Update Il y a 4 ans
Efficacy of agomelatine given orally on the quality of remission in elderly depressed patients, after a 12-week treatment period. A randomised, double-blind, flexible-dose international multicentre study with parallel groups versus SSRI drug. Twelve-week treatment plus optional continuation for 12 weeks
Not provided at time of registration and not expected to be available in the future
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Institut de Recherches Internationales Servier (France)
Update Il y a 4 ans
The EUROPA study: EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery
Not provided at time of registration and not expected to be available in the future
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Institut de Recherches Internationales Servier (France)
Update Il y a 4 ans
Clinical efficacy of Valdoxan® in everyday practice conditions (efficiency)
Not provided at time of registration and not expected to be available in the future
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Institut de Recherches Internationales Servier (France)
Update Il y a 4 ans
Clinical acceptability study in patients suffering from chronic venous disease (CVD) comparing micronized purified flavonoid fraction (MPFF) 1000 mg, one tablet daily, to MPFF 500 mg tablet twice a day
Not provided at time of registration and not expected to be available in the future
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Institut de Recherches Internationales Servier (France)
Update Il y a 4 ans
Effects of micronised purified flavonoic fraction on microcirculation in women suffering from chronic venous disease
Not provided at time of registration and not expected to be available in the future
Country
None
organs
None
Specialty
None
Closed trial
More information
1
2
3
4
5
6
Next